<DOC>
	<DOCNO>NCT01849640</DOCNO>
	<brief_summary>This two-arm , open label Treatment Study compare efficacy , safety , tolerability pharmacokinetics three-day course Dihydroartemisinin-Piperaquine ( DP ) without single-dose primaquine patient uncomplicated Plasmodium falciparum malaria . On last day DP therapy , volunteer randomize receive either single 45 mg dose primaquine ( PQ ) DP treatment ( primaquine ) .</brief_summary>
	<brief_title>Antimalarial Drug Resistance With Assessment Transmission Blocking Activity</brief_title>
	<detailed_description>Volunteers uncomplicated malaria Cambodia enrol current standard care therapy DHA-piperaquine monitor therapeutic efficacy measure resistance . The cardiac safety piperaquine monitor electrocardiograms treatment period . Resistance DP DP-PQ assess combination clinical , pharmacologic , parasitologic parameter include genomic signature selection careful weekly follow-up visit 42 day . Volunteers randomize day 3 either single 45mg dose primaquine sexual stage therapy evaluate effect primaquine sexual stage malaria ( gametocyte ) potential transmissibility infection Anopheles mosquito compare treated primaquine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Volunteer uncomplicated P. falciparum malaria ( volunteer mix P. falciparum P. vivax infection may enrol ) , 1865 year age 2 . Baseline asexual parasite density 1,000200,000 parasites/uL 3 . Able provide inform consent 4 . Available agree followup anticipate study duration include 3 day treatment course MTF weekly followup 42day period 5 . Authorized local commander participate active duty military 1 . Allergic reaction contraindication DHA , piperaquine primaquine 2 . Significant acute comorbidity require urgent medical intervention 3 . Signs/symptoms parasitological confirmation severe malaria 4 . Use antimalarial within past 14 day . 5 . Class I II G6PD deficiency ( define severe ) determine screen 6 . Pregnant lactate female , female childbearing age , 50 year age , agree use acceptable form contraception study 7 . Clinically significant abnormal EKG , include QTcF interval &gt; 500 ms enrollment . 8 . Known suspected concomitant use QTc prolonging medication . 9 . Judged investigator otherwise unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>DHA-piperaquine</keyword>
	<keyword>Cambodia</keyword>
	<keyword>Transmission Blocking</keyword>
</DOC>